Thus, research has shown that HER2/low IBC is a heterogeneous disease that can exhibit different molecular characteristics and behaviors depending on the specific subtype associated with distinct prognostic outcomes compared to other breast cancers and systemic therapies such as hormonotherapy and anti-HER-2 targeted therapy were effective in treating IBC. This evidence concerns the gene ERBB2 and breast cancer.